Mannkind Corp(MNKD) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 5 at 6:10 PM ET (Korea 11/6 08:10)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.14 | Insider Own | 4.53% | Shs Outstand | 309.9M | Perf Week | 7.43% |
| Market Cap | 1.21B | Forward P/E | 1129.13 | EPS next Y | 101.75% | Insider Trans | -1.41% | Shs Float | 307.0M | Perf Month | 8.99% |
| Enterprise Value | 1.53B | PEG | 27.05 | EPS next Q | -0.06 | Inst Own | 54.72% | Short Float | 8.3% | Perf Quarter | -8.52% |
| Income | -0.04B | P/S | 3.07 | EPS this Y | -1050% | Inst Trans | -3.91% | Short Ratio | 6.14 | Perf Half Y | 5.92% |
| Sales | 0.39B | P/B | - | EPS next 5Y | 41.75% | ROA | -7.62% | Short Interest | 25.48M | Perf YTD | -33.69% |
| Book/sh | -0.22 | P/C | 10.88 | EPS past 3/5Y | - | ROE | - | 52W High | -42.24% ($6.51) | Perf Year | -37.95% |
| Cash/sh | 0.35 | P/FCF | - | Sales past 3/5Y | 51.8% 39.89% | ROIC | -12.25% | 52W Low | 68.61% ($2.23) | Perf 3Y | -5.05% |
| Dividend Est. | - | EV/EBITDA | 44.04 | EPS Y/Y TTM | -223.84% | Gross Margin | 72.16% | Volatility(W/M) | 4.44% 5.29% | Perf 5Y | -21.83% |
| Dividend TTM | - | EV/Sales | 3.9 | Sales Y/Y TTM | 30.46% | Oper. Margin | 3.37% | ATR (14) | 0.19 | Perf 10Y | 74.88% |
| Dividend Ex-Date | - | Quick Ratio | 1.41 | EPS Q/Q | -3033.33% | Profit Margin | -11.08% | RSI (14) | 60.68 | Recom | 1.22 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.72 | Sales Q/Q | 42.92% | SMA20 | 13.3% ($3.32) | Beta | 1.1 | Target Price | $8.08 |
| Payout | - | Debt/Eq | - | Earnings | 2026/11/5 | SMA50 | 5.77% ($3.55) | Rel Volume | 1.3 | Prev Close | $3.93 |
| Employees | 592 | LT Debt/Eq | - | EPS/Sales Surpr. | -700% 1.2% | SMA200 | 1.76% ($3.69) | Avg Volume(3M) | 4.15M | Price | $3.76 |
| IPO | 2004/7/28 | Option/Short | Yes/Yes | Trades | 12901 | Volume | 5,388,189 | Change | -4.33% |
💉 MannKind (MNKD) is a US biotech company built around inhaled drug delivery technology. It directly markets inhaled insulin Afrezza and licenses its dry-powder inhalation technology to partner United Therapeutics for their inhaled pulmonary hypertension therapy Tyvasso, generating royalty income. The company has also expanded into endocrinology and rare diseases with its heart failure treatment Furoscix.
Over the past 1 year, roughly in the middle
42% below its 1-year high.
Traded more than usual. That is 130% of its average volume.
MNKD keeps an operating profit but posts a net loss
Of every $100 in sales, $3.37 is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -1050.0% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $307. Peers typically go for $1,160. Compared with its own 2-year average, it is 64% pricier now.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -21.8%. The S&P 500 did +56% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 54.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #143 of 597 in the industry
Based on market cap of $1B.
FAQ
What kind of company is MNKD?
MNKD belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of MNKD?
The market cap of MNKD is approximately $1.2B, ranking 2,416 within its sector.
What is the 52-week high and low for MNKD?
MNKD has recorded a 52-week high of $6.51 and a low of $2.23.
